Immunosuppression Regimen Use and Outcomes in Older and Younger Adult Kidney Transplant Recipients: A National Registry Analysis.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Alemtuzumab
/ administration & dosage
Antilymphocyte Serum
/ administration & dosage
Female
Graft Rejection
Humans
Immunosuppressive Agents
/ administration & dosage
Kidney Transplantation
/ adverse effects
Male
Middle Aged
Receptors, Interleukin-2
/ antagonists & inhibitors
Registries
Young Adult
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
21
11
2020
medline:
13
8
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
Although the population of older transplant recipients has increased dramatically, there are limited data describing the impact of immunosuppression regimen choice on outcomes in this recipient group. National data for US Medicare-insured adult kidney recipients (N = 67 362; 2005-2016) were examined to determine early immunosuppression regimen and associations with acute rejection, death-censored graft failure, and mortality using multivariable regression analysis in younger (18-64 y) and older (>65 y) adults. The use of antithymocyte globulin (TMG) or alemtuzumab (ALEM) induction with triple maintenance immunosuppression (reference) was less common in older compared with younger (36.9% versus 47.0%) recipients, as was TMG/ALEM + steroid avoidance (19.2% versus 20.1%) and mammalian target of rapamycin inhibitor (mTORi)-based (6.7% versus 7.7%) treatments. Conversely, older patients were more likely to receive interleukin (IL)-2-receptor antibody (IL2rAb) + triple maintenance (21.1% versus 14.7%), IL2rAb + steroid avoidance (4.1% versus 1.8%), and cyclosporine-based (8.3% versus 6.6%) immunosuppression. Compared with older recipients treated with TMG/ALEM + triple maintenance (reference regimen), those managed with TMG/ALEM + steroid avoidance (adjusted odds ratio [aOR], 0.440.520.61) and IL2rAb + steroid avoidance (aOR, 0.390.550.79) had lower risk of acute rejection. Older patients experienced more death-censored graft failure when managed with Tac + antimetabolite avoidance (adjusted hazard [aHR], 1.411.782.25), mTORi-based (aHR, 1.702.142.71), and cyclosporine-based (aHR, 1.411.782.25) regimens, versus the reference regimen. mTORi-based and cyclosporine-based regimens were associated with increased mortality in both older and younger patients. Lower-intensity immunosuppression regimens (eg, steroid-sparing) appear beneficial for older kidney transplant recipients, while mTORi and cyclosporine-based maintenance immunosuppression are associated with higher risk of adverse outcomes.
Sections du résumé
BACKGROUND
Although the population of older transplant recipients has increased dramatically, there are limited data describing the impact of immunosuppression regimen choice on outcomes in this recipient group.
METHODS
National data for US Medicare-insured adult kidney recipients (N = 67 362; 2005-2016) were examined to determine early immunosuppression regimen and associations with acute rejection, death-censored graft failure, and mortality using multivariable regression analysis in younger (18-64 y) and older (>65 y) adults.
RESULTS
The use of antithymocyte globulin (TMG) or alemtuzumab (ALEM) induction with triple maintenance immunosuppression (reference) was less common in older compared with younger (36.9% versus 47.0%) recipients, as was TMG/ALEM + steroid avoidance (19.2% versus 20.1%) and mammalian target of rapamycin inhibitor (mTORi)-based (6.7% versus 7.7%) treatments. Conversely, older patients were more likely to receive interleukin (IL)-2-receptor antibody (IL2rAb) + triple maintenance (21.1% versus 14.7%), IL2rAb + steroid avoidance (4.1% versus 1.8%), and cyclosporine-based (8.3% versus 6.6%) immunosuppression. Compared with older recipients treated with TMG/ALEM + triple maintenance (reference regimen), those managed with TMG/ALEM + steroid avoidance (adjusted odds ratio [aOR], 0.440.520.61) and IL2rAb + steroid avoidance (aOR, 0.390.550.79) had lower risk of acute rejection. Older patients experienced more death-censored graft failure when managed with Tac + antimetabolite avoidance (adjusted hazard [aHR], 1.411.782.25), mTORi-based (aHR, 1.702.142.71), and cyclosporine-based (aHR, 1.411.782.25) regimens, versus the reference regimen. mTORi-based and cyclosporine-based regimens were associated with increased mortality in both older and younger patients.
CONCLUSIONS
Lower-intensity immunosuppression regimens (eg, steroid-sparing) appear beneficial for older kidney transplant recipients, while mTORi and cyclosporine-based maintenance immunosuppression are associated with higher risk of adverse outcomes.
Identifiants
pubmed: 33214534
pii: 00007890-202108000-00029
doi: 10.1097/TP.0000000000003547
pmc: PMC10576532
mid: NIHMS1646489
doi:
Substances chimiques
Antilymphocyte Serum
0
Immunosuppressive Agents
0
Receptors, Interleukin-2
0
Alemtuzumab
3A189DH42V
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1840-1849Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK120518
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Transplantation. 1999 Nov 27;68(10):1496-502
pubmed: 10589946
Transplantation. 2012 Aug 27;94(4):369-76
pubmed: 22836133
Am J Transplant. 2020 Jan;20 Suppl s1:20-130
pubmed: 31898417
Am J Transplant. 2012 Dec;12(12):3326-36
pubmed: 22947444
Eur Urol. 2005 Feb;47(2):156-66
pubmed: 15661409
Transplantation. 2010 Aug 27;90(4):343-9
pubmed: 20574419
Am J Kidney Dis. 2013 May;61(5):790-7
pubmed: 23261121
Adv Chronic Kidney Dis. 2010 Jul;17(4):293-301
pubmed: 20610356
J Am Soc Nephrol. 2005 Jun;16(6):1859-65
pubmed: 15857921
Am J Kidney Dis. 2019 Mar;73(3 Suppl 1):A7-A8
pubmed: 30798791
J Am Soc Nephrol. 2004 Mar;15(3):809-17
pubmed: 14978184
Transplantation. 2014 Apr 27;97(8):832-8
pubmed: 24342978
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005632
pubmed: 19160257
Transpl Int. 2016 Nov;29(11):1226-1236
pubmed: 27564782
Transplantation. 2006 Dec 27;82(12):1673-6
pubmed: 17198258
Clin J Am Soc Nephrol. 2011 May;6(5):1168-78
pubmed: 21511836
Lancet Infect Dis. 2002 Nov;2(11):659-66
pubmed: 12409046
Transplantation. 2000 Mar 15;69(5):794-9
pubmed: 10755528
Kidney Int Rep. 2019 Jan 28;4(5):656-666
pubmed: 31080920
Transplantation. 2007 Aug 15;84(3):285-91
pubmed: 17700150
Clin Transplant. 2004 Aug;18(4):446-9
pubmed: 15233824
N Engl J Med. 2005 Mar 31;352(13):1317-23
pubmed: 15800227
Transplantation. 2017 Mar;101(3):588-596
pubmed: 26985745
Transplantation. 2007 Feb 27;83(4):404-10
pubmed: 17318072
Transplant Proc. 2004 Nov;36(9):2646-8
pubmed: 15621113
Clin Transplant. 2005 Jun;19(3):309-15
pubmed: 15877790
Transplantation. 2012 Aug 15;94(3):241-9
pubmed: 22874796
Drugs Aging. 2005;22(7):541-57
pubmed: 16038570
Front Immunol. 2018 Jan 10;8:1960
pubmed: 29375577
Transplantation. 2000 Mar 15;69(5):790-4
pubmed: 10755527
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003961
pubmed: 16235347
Transplantation. 2005 Sep 27;80(6):749-58
pubmed: 16210961
Nephrol Dial Transplant. 2012 Feb;27(2):825-32
pubmed: 21785040
Am J Transplant. 2018 May;18(5):1168-1176
pubmed: 29451350
Transplantation. 2005 Oct 15;80(7):883-9
pubmed: 16249734
Int Urol Nephrol. 2009;41(1):195-210
pubmed: 18989746
Transplant Rev (Orlando). 2020 Apr;34(2):100529
pubmed: 31948863
Transplantation. 2000 Mar 15;69(5):885-9
pubmed: 10755545
Am J Transplant. 2019 Nov;19(11):3018-3034
pubmed: 31152476
Am J Transplant. 2006;6(5 Pt 2):1111-31
pubmed: 16613591
Transplantation. 2005 Oct 15;80(7):989-92
pubmed: 16249750
Am J Kidney Dis. 1992 Nov;20(5 Suppl 2):68-83
pubmed: 1442778
Transplantation. 2000 Jul 27;70(2):306-10
pubmed: 10933154
Front Immunol. 2020 Mar 12;11:359
pubmed: 32226428
Transplantation. 2005 Oct 15;80(7):953-8
pubmed: 16249744
Transplantation. 2003 Jul 27;76(2):441-2
pubmed: 12883215
Transplantation. 2017 Apr;101(4):867-872
pubmed: 27495758
Am J Transplant. 2009 Mar;9(3):527-35
pubmed: 19191769
Transplant Rev (Orlando). 2015 Oct;29(4):191-2
pubmed: 26586643
Am J Transplant. 2009 Nov;9 Suppl 3:S1-155
pubmed: 19845597
Semin Nephrol. 2009 Nov;29(6):621-35
pubmed: 20006794
Transplantation. 2005 Jan 27;79(2):127-32
pubmed: 15665758
Transplantation. 2010 Nov 15;90(9):974-9
pubmed: 20814353
PLoS One. 2019 Sep 19;14(9):e0222730
pubmed: 31536556
Nat Rev Nephrol. 2012 Dec;8(12):700-8
pubmed: 23147756
Transplantation. 2013 Dec 27;96(12):1089-96
pubmed: 24056622
Cochrane Database Syst Rev. 2016 Aug 22;(8):CD005632
pubmed: 27546100
Transplantation. 2003 Aug 15;76(3):619
pubmed: 12923455
Kidney Int. 2001 Apr;59(4):1539-43
pubmed: 11260418
Am J Transplant. 2016 Aug;16(8):2453-62
pubmed: 26901466
Kidney Int. 2000 Jan;57(1):307-13
pubmed: 10620213
Transplantation. 2020 Feb;104(2):349-356
pubmed: 31343576